anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a vaccine containing an antibody originated from an immunized animal of the family Bovidae and enabling safe heterologous passive immunization of mammals without causing anaphylactic reaction, etc., by the administration to a mammal having immunity tolerance acquired by the intake of the milk of the animal. SOLUTION: This vaccine suitable for parenteral administration is composed of (A) an antibody (preferably IgG antibody, etc.) of an animal of the family Bovidae (preferably cattle) immunized with an antigen (e.g. bacterial antigen and bee toxin) inducing a certain state to the mammal and (B) a carrier. It is originated from the milk of a bovine animal immunized with the above antigen and constructed to be administered to a mammal having tolerance acquired by the repeated feeding of the mammal with an immunotherapeutic food having an antibody titer sufficiently increased to enable the induction of the tolerance against the above antibody. The vaccine is preferably produced from the milk or serum of an animal of the family Bovidae.
Disclosed is a secure telephone call management system for authenticating users of a telephone system in an institutional facility. Authentication of the users is accomplished by using a personal identification number, preferably in conjunction with speaker independent voice recognition and speaker dependent voice identification. When a user first enters the system, the user speaks his or her name which is used as a sample voice print. During each subsequent use of the system, the user is required to speak his or her name. Voice identification software is used to verify that the provided speech matches the sample voice print. The secure system includes accounting software to limit access based on funds in a user's account or other related limitations. Management software implements widespread or local changes to the system and can modify or set any number of user account parameters.
PURPOSE: A pharmaceutical composition for enhancing radiation therapy for cancer is provided to ensure sensitivity of cancer cells on radiation. CONSTITUTION: A pharmaceutical composition for enhancing radiation therapy for cancer contains a function inhibitor of binding between DNA-PKcs and transcription factor Snail 1 protein. The function inhibitor is an antisense oligonucleotide to Snail 1 gene; minigene encoding antipeptide of Snail ; or binding inhibitor of Snail 1 with DNA-PKcs. The antipeitide to Snail 1 contains KPNYSEL(SEQ ID NO. 1) or KPSDPNRKPNYSELQ DSNPEFTFQQPY(SEQ ID NO. 2). A method for screening an active material for enhancing radiation therapy for cancer comprises: a step of treating cancer cell line with each sample; a step of measuring the expression of Snail gene in the cancer cell line; and a step of selecting a sample which suppresses Snail 1 gene expression.
The invention provides a preparation method of polysaccharide-based polymer self-assembled nano vesicles. Firstly, initiating the ring opening of caprolactone (. epsilon. -CL) by hydroxyethyl isobromisobutyrate (HEBIB) to form a PCL macroinitiator (PCL-HEBIB) which can be used for ATRP reaction; the method utilizes acryloyl chloride to modify dextran to form dextran macromonomers with double bonds. The dextran macromonomer is successfully grafted to the PCL macroinitiator through ATRP reaction to form the amphiphilic polymer. The nano-carrier can be self-assembled in water to form nano-vesicles for encapsulating hydrophilic drugs, and has good biocompatibility and biodegradability. The glycosyl skeleton of the dextran can be fused with a cell membrane, so that the nano-particle can be effectively internalized by cells. The nanovesicles break down under intracellular enzymatic degradation reactions, releasing the encapsulated drug. The characteristic enables the nano-carrier to have better hydrophilic drug loading capacity and potential therapeutic application of intracerebral diseases.
Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The invention relates to the technical field of health products, in particular to an anti-radiation composition and a preparation method thereof. Apple stem cell freeze-dried powder, a lucid ganoderma extract and a rhodiola rosea extract are compounded to achieve a remarkable anti-radiation function. Experiments show that the anti-radiation effect of the composition provided by the invention is obviously superior to the effect caused by independent use of each component. The rat testicle cell chromosome aberration test through repeated irradiation within 30 days shows that the aberrant cell rate of a blank control group is 21.67%. By adoption of the composition provided by the invention, the aberrant cell rate is reduced to 7.33%, and the effect is obviously superior to independent use of the apple stem cells, or the lucid ganoderma extract or the rhodiola rosea extract. The rat marrow osteocyte micronuclear test through repeated irradiation within 30 days shows the micronucleus rate of the blank control group is 0.117%. By adoption of the composition provided by the invention, the micronucleus rate can be improved to 1.27%, so that the effect is obviously superior to independent use of the apple stem cells, or the ganoderma extract or the rhodiola rosea extract.
Renal Toxicity

ZYNRELEF is a single-use product that contains an NSAID. Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

The renal effects of meloxicam may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.

Correct volume status in dehydrated or hypovolemic patients prior to initiating ZYNRELEF. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of ZYNRELEF [see Drug Interactions (7)]. Avoid the use of ZYNRELEF in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If ZYNRELEF is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [see Clinical Pharmacology (12.3)].

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
BACKGROUND: Evidence of the effects of metabolically healthy obesity (MHO) on atherosclerosis is limited; the transition effects of metabolic health and obesity phenotypes have been ignored. We examined the association between metabolic health and the transition to atherosclerosis risk across body mass index (BMI) categories in a community population.
METHODS: This cross-sectional study was based on a national representative survey that included 50,885 community participants aged ≥40 years. It was conducted from 01 December 2017 to 31 December 2020, in 13 urban and 13 rural regions across Hunan China. Metabolic health was defined as meeting less than three abnormalities in blood pressure, glucose, high-density lipoprotein cholesterol, triglycerides, or waist circumference. The participants were cross-classified at baseline based on their metabolic health and obesity. In addition, the relationship between atherosclerosis and transitions in metabolic health status based on 4733 participants from baseline to the second survey after 2 years was considered. The relationship between metabolic health status and the risk of transition to Carotid atherosclerosis (CA) was assessed using logistic regression and Cox proportional hazards regression analyses.
RESULTS: In this study, the mean age of the participants was 60.7 years (standard deviation [SD], 10.91), 53.0% were female, and 51.2% had CA. As compared with metabolically healthy normal weight (MHN), those with MHO phenotype (odd ratio [OR] 1.10, 95% confidence interval [CI] 1.02-1.21), metabolically unhealthy normal weight (OR 1.27, 95% CI 1.19-1.35), metabolically unhealthy overweight (OR 1.41, 95% CI 1.33-1.48), and metabolically unhealthy obese (OR 1.54, 95% CI 1.44-1.64) had higher risk for CA. However, during the follow-up of 2 years, almost 33% of the participants transitioned to a metabolically unhealthy status. As compared with stable healthy normal weight, transition from metabolically healthy to unhealthy status (hazard ratios [HR] 1.21, 95% [CI] 1.02-1.43) and stable metabolically unhealthy overweight or obesity (MUOO) (HR 1.32, 95% CI 1.17-1.48) were associated with higher risk of CA.
CONCLUSIONS: In the community population, obesity remains a risk factor for CA despite metabolic health. However, the risks were highest for metabolically unhealthy status across all BMI categories. A large proportion of metabolically healthy overweight or participants with obesity converts to an unhealthy phenotype over time, which is associated with an increased risk of CA.
Alcohol use disorder, reported by 1 in 8 critically ill patients, is a risk factor for death in sepsis patients. Sepsis, the leading cause of death, kills over 270,000 patients in the United States alone and remains without targeted therapy. Immune response in sepsis transitions from an early hyperinflammation to persistent inflammation and immunosuppression and multiple organ dysfunction during late sepsis. Innate immunity is the first line of defense against pathogen invasion. Ethanol exposure is known to impair innate and adaptive immune response and bacterial clearance in sepsis patients. Specifically, ethanol exposure is known to modulate every aspect of innate immune response with and without sepsis. Multiple molecular mechanisms are implicated in causing dysregulated immune response in ethanol exposure with sepsis, but targeted treatments have remained elusive. In this article, we outline the effects of ethanol exposure on various innate immune cell types in general and during sepsis.
Intravenous pembrolizumab 400 mg Q6W + oral encorafenib 450 mg QD + oral binimetinib 45mg BID, for the first 4 weeks of the study. Starting week 5, monotherapy pembrolizumab 400 mg Q6W.
An optimization system optimizes groups of providers for a given population of users. The optimization system includes various engines such as a source interface engine, selection engine, and group score engine. The source interface engine receives information to be used in constrained optimization from server computers and stores the information in databases. The selection engine selects groups of providers from a set of all available providers. The group score engine generates a score for each group of providers. The selection engine continues to iteratively select groups of providers to minimize the generated score. The selection engine can use hard constraints, for example, requiring that a certain type of provider be included in all selected groups, or soft constraints, for example, requiring that a certain number of providers be included based on a size of the given population.
The present application belongs to the technical ﬁeld of microorganism applications, and speciﬁcally relates to a novel application of bifidobacterium lactis TY—SOl in weight control. The bifidobacterium lactis TY—SOl is assigned with the accession number of CGMCC No. 10 21255. The bifidobacterium lactis TY—SOl may signiﬁcantly reduce body weight and abdominal fat, signiﬁcantly reduce triglyceride and cholesterol levels in liver tissue, signiﬁcantly promote secretion of a short-chain fatty acid (acetic acid) in an intestinal tract, and signiﬁcantly regulate intestinal ﬂora disorders in a human body, and the bifidobacterium lactis TY—SOl has no toxic and side effects, and is high in safety. 15 Fig. 3
A long-term study of tazarotene following oral administration of 0.025, 0.050, and 0.125 mg/kg/day to rats showed no indications of increased carcinogenic risks. Based on pharmacokinetic data from a shorter-term study in rats, the highest dose of 0.125 mg/kg/day was anticipated to give systemic exposure in the rat 0.3 times that seen in subjects treated with the MRHD of tazarotene gel, 0.1%.

A long-term study with topical administration of up to 0.1% tazarotene in a gel formulation in mice terminated at 88 weeks showed that dose levels of 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced to 0.5 mg/kg/day for males after 41 weeks due to severe dermal irritation) revealed no apparent carcinogenic effects when compared to vehicle control animals. Systemic exposure at the highest dose was 2 times that seen in subjects treated with the MRHD of tazarotene gel, 0.1%.

Tazarotene was non-mutagenic in the Ames assay and did not produce structural chromosomal aberrations in a human lymphocyte assay. Tazarotene was non-mutagenic in the CHO/HGPRT mammalian cell forward gene mutation assay and was non-clastogenic in the in vivo mouse micronucleus test.

No impairment of fertility occurred in rats when male animals were treated for 70 days prior to mating and female animals were treated for 14 days prior to mating and continuing through gestation and lactation with topical doses of tazarotene gel up to 0.125 mg/kg/day. Based on data from another study, the systemic drug exposure in the rat at the highest dose was 0.3 times that observed in subjects treated with the MRHD of tazarotene gel, 0.1%. 

No impairment of mating performance or fertility was observed in male rats treated for 70 days prior to mating with oral doses of up to 1 mg/kg/day tazarotene, which produced systemic exposure that was approximately equivalent to that observed in subjects treated with the MRHD of tazarotene gel, 0.1%. 

No impairment of mating performance or fertility was observed in female rats treated for 15 days prior to mating and continuing through gestation day 7 with oral doses of tazarotene up to 2 mg/kg/day. However, there was a significant decrease in the number of estrous stages and an increase in developmental effects at that dose, which produced systemic exposure 2 times that observed in subjects treated with the MRHD of tazarotene gel, 0.1% [see Use in Specific Populations (8.1)].
<P>PROBLEM TO BE SOLVED: To provide a prophylactic and/or a therapeutic agent for aneurysm, capable of pharmaceutically preventing occurrence or enlargement of a lump or capable of inhibiting rupture thereof when the lump is degenerated, while the aneurysm is a clinically important disease leading to death due to the rupture and an invasive surgical treatment is a solely existing treatment therefor.  <P>SOLUTION: This prophylactic and/or therapeutic agent for the aneurysm contains a JNK (c-Jun N-terminal kinase) inhibitor as an active ingredient. The JNK inhibitor is, in details, developed based on new discovery that acceleration of decomposition of an extracellular substrate of an arterial wall and inhibition of regeneration thereof are simultaneously caused by activation of the JNK. Therefore, the JNK inhibitor synthetically rectifies various factors of the above and further prevents collapse of the extracellular substrate. Further, the inhibitor prevents onset, progress, and the rupture of the aneurysm and, still more, improves life and prognosis of a patient suffering from the aneurysm.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
Suppression of neuroinflammation using small molecule compounds targeting the key pathways in microglial inflammation has attracted great interest. Recently, increasing attention has been gained to the role of the second bromodomain (BD2) of the bromodomain and extra-terminal (BET) proteins, while its effect and molecular mechanism on microglial inflammation has not yet been explored. In this study, we evaluated the therapeutic effects of ABBV-744, a BD2 high selective BET inhibitor, on lipopolysaccharide (LPS)-induced microglial inflammation in vitro and in vivo, and explored the key pathways by which ABBV-744 regulated microglia-mediated neuroinflammation. We found that pretreatment of ABBV-744 concentration-dependently inhibited the expression of LPS-induced inflammatory mediators/enzymes including NO, TNF-α, IL-1β, IL-6, iNOS, and COX-2 in BV-2 microglial cells. These effects were validated in LPS-treated primary microglial cells. Furthermore, we observed that administration of ABBV-744 significantly alleviated LPS-induced activation of microglia and transcriptional levels of pro-inflammatory factors TNF-α and IL-1β in mouse hippocampus and cortex. RNA-Sequencing (RNA-seq) analysis revealed that ABBV-744 induced 508 differentially expressed genes (DEGs) in LPS-stimulated BV-2 cells, and gene enrichment and gene expression network analysis verified its regulation on activated microglial genes and inflammatory pathways. We demonstrated that pretreatment of ABBV-744 significantly reduced the expression levels of basic leucine zipper ATF-like transcription factor 2 (BATF2) and interferon regulatory factor 4 (IRF4), and suppressed JAK-STAT signaling pathway in LPS-stimulated BV-2 cells and mice, suggesting that the anti-neuroinflammatory effect of ABBV-744 might be associated with regulation of BATF2-IRF4-STAT1/3/5 pathway, which was confirmed by gene knockdown experiments. This study demonstrates the effect of a BD2 high selective BET inhibitor, ABBV-744, against microglial inflammation, and reveals a BATF2-IRF4-STAT1/3/5 pathway in regulation of microglial inflammation, which might provide new clues for discovery of effective therapeutic strategy against neuroinflammation.
BACKGROUND: Intracranial plasmacytomas are rare tumors arising from plasma cells with approximately half of the cases progressing to multiple myeloma (MM). However, there is a lack of comprehensive clinical cohort analysis on the clinical and pathological features, progression, and outcomes of intracranial plasmacytomas.
METHODS: A retrospective analysis of 190 cases was conducted, combining data from 38 cases in a single institution and 152 cases from the literature. Patient demographics, clinical presentations, tumor locations, imaging features, surgical treatments, and follow-up outcomes were collected and analyzed. Survival analysis and Cox regression analysis were performed to identify prognostic factors.
RESULTS: A total of 190 intracranial plasmacytoma patients with an average age of 55.4 years were included in the study. The preoperative misdiagnosis ratio was high at 55.3%, and 59.7% of the tumors affected the calvaria convexity, compared to 40.3% located at the skull base. Resection and biopsy were achieved in 72.4% and 27.6% patients, respectively. Among them, 34.2% (65/190) of patients were initially diagnosed with MM with intracranial plasmacytoma as their first presentation (MM-IPFP), while 63.2% (120/190) of patients were diagnosed with solitary intracranial plasmacytoma (SIP), including 61 extramedullary plasmacytomas and 59 solitary bone plasmacytomas. In the SIP group, 22.4% (24/107) of patients experienced disease progression leading to the development of MM during a median follow-up time of 42.6 months (range 1-230 months). Multivariate analysis unveiled that radiotherapy (HR, 0.05; 95% CI, 0.00-0.87; p = 0.04), not surgery, was a protective prognostic factor for overall survival in MM-IPFP patients. Comparison between the SIP progression group and non-progression group revealed a significant difference of Ki-67 index (non-progression vs. SIP progression, 8.82% ± 7.03 vs. 16.5% ± 10.5, p < 0.05). AUC analysis determined that a cutoff value of 9.0% was the best predictor of SIP progression, with an area under the curve of 0.712.
CONCLUSIONS: This retrospective clinical analysis highlights the potential role of radiotherapy, rather than surgical resection, in improving the outcomes of intracranial plasmacytoma. Additionally, the Ki-67 index is identified as a valuable marker for predicting disease progression. This would provide some evidence for the paradigm of diagnosis and treatment modalities for intracranial plasmacytomas from the large cohort.
In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
OBJECTIVE: In this study, the relationship between maximum carotid plaque area and stroke prognosis was analysed by carotid ultrasonography, and the relevant risk factors affecting the prognosis of acute ischaemic stroke (AIS) were investigated to provide novel insights into stroke prevention and management.
METHODS: A total of 205 AIS patients with carotid plaques were included in this study. Based on the mRS score at discharge, patients with AIS were classified into the good prognosis group (mRS ≤ 2) and poor prognosis group (mRS ≥ 3). SPSS 25.0 was used to analyse the data. Univariate and multivariate analyses were performed on the two groups with good and poor prognosis. Comparison between good and poor prognosis in patients with AIS in different circulatory systems was performed using the Kruskal-Wallis test. Differences were considered statistically significant at P < 0.05.
RESULTS: Comparison of baseline data revealed differences in carotid plaque diameter, carotid intima-media thickness, maximum carotid plaque area, history of previous stroke and plaque echogenicity between the good and poor prognosis groups (P < 0.05). Results of multifactorial analyses of logistic binary regression indicated that history of previous stroke and maximum carotid plaque area were predictors of poor prognosis, with odds ratio of 2.515 (95%CI [1.327-4.764]) and 1.019 (95%CI [1.006-1.032]), respectively.
CONCLUSION: The maximum carotid plaque area and history of previous stroke are important predictors for assessing prognosis in patients with AIS.